Deglycyrrhizinated licorice, or DGL, has been used clinically for decades, primarily for the treatment of peptic ulcers. Licorice has many triterpenoids and hundreds of fl avonoids that have been shown to inhibit several infl ammatory enzymes, including both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). These enzymes increase the production of several potent infl ammatory compounds, including IL-6, prostaglandin E2, thromboxane B2, and leukotriene B4. Importantly, this inhibition is not primarily due to glycyrrhizic acid, the component of licorice that has been removed in DGL and that is associated with mineralocorticoid excess and hypertension. Licorice has multiple active compounds with anti-infl ammatory, antimicrobial, and anti-allergic actions, including glabridin and at least seven licochalcones. The compounds have been shown to prevent lipopolysaccharide (LPS) induced production of infl ammatory compounds, inhibit yeast and bacterial biofi lm formation, and upregulate antioxidant enzymes.
Clinically, DGL has been shown to have comparable effi cacy to cimetidine for both the healing and prevention of ulcer recurrences. Additionally, extracts of licorice have been shown to inhibit the adhesion of H. pylori to gastric mucosa, as well as the growth of antibiotic resistant strains, suggesting multiple mechanisms of action for its anti-ulcer benefit. The use of chewable tablets appears necessary for DGL’s effi cacy as it allows for distribution and absorption by the gastric mucosa
Each Tablet Contains:
Deglycyrrhizinated Licorice 10:1 Extract (Glycyrrhiza glabra) (root) 400 mg
Providing 4,000 mg crude herb licorice
Recommended Use:
Chew 1 tablet 20 minutes prior to each meal, or as directed by a health care practitioner.
180 Chewable Tablets
NPN: 80037407